| Catalog No. | HY255016 |
|---|
| Species reactivity | Human |
|---|
| Applications | Research Grade Biosimilar |
|---|
| Host species | Humanized |
|---|
| Isotype | VH-VH |
|---|
| Expression system | Mammalian Cells |
|---|
| Clonality | Monoclonal |
|---|
| Target | von Willebrand antigen II, von Willebrand factor, F8VWF, vWF, VWF |
|---|
| Concentration | 1.6mg/ml |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G, purified from cell culture supernatant. |
|---|
| Accession | P04275 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 20mM citric acid,6.2% sucrose,0.01% Tween80 |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -606°C. |
|---|
| Alternate Names | ALX-0081,PMP12A2h1-linkerAAA-PMP12A2h1,caplacizumab-yhdp,CAS:915810-67-2 |
|---|
| Background | Caplacizumab (ALX-0681) is a humanized anti-von Willebrand factor (vWF) nanobody. Caplacizumab inhibits the vWF-mediated platelet adhesion and prevents further microthrombi formation. Caplacizumab can be used for the research of thrombotic thrombocytopenic purpura (TTP). |
|---|
| Note | For research use only. Not for use in clinical or therapeutic applications. |
|---|
